Welcome to Clavis Pharma

The Key to Improved Cancer Therapy

Clavis Pharma ASA is a clinical-stage oncology focused pharmaceutical company with a portfolio of novel anti-cancer drugs in development, including two candidates in pivotal clinical studies.

These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration, altered metabolism and, in certain cases, additional modes of action.